Innovating Upstream AAV Manufacturing for the Next Wave of Gene Therapies

WEBINAR

Adeno-associated viruses (AAVs) have emerged as a leading vector for gene therapies. Platform solutions offer a well-known approach for addressing the inherent complexity, and inconsistent yields often associated with transient AAV production.

In this webinar, we explore the AAViator™ Production Platform, a novel transfection solution for transient AAV production in HEK293 cells. We will discuss studies comparing the AAViator™ Production Platform's performance to commercially available polymer-only and lipid-only transient transfection reagents. Additionally, we will evaluate the platform across various AAV serotypes, transgenes/gene of interest (GOI), and HEK293 cell lineages at small and bench bioreactor scales. Finally, we will examine how this versatile solution can reduce batch costs and costs per dose.

In this webinar, you will learn:

• How the AAViator™ Production Platform can maximize yields across multiple AAV serotypes (AAV5, AAV8, AAV9) and various HEK293-based cell lines. 
• How a platform approach can streamline AAV upstream process development by minimizing the need for extensive optimization of transfection reagents and media.
• Methodologies for optimizing key transfection parameters for AAV manufacturing. 
• Key learnings for successful scale up of transient AAV processes to bench-scale stirred-tank bioreactors.
• Ways an optimized upstream process can help manage batch costs and costs per dose for scalability and commercial viability